AKR1C3 expression in T acute lymphoblastic leukemia/lymphoma for clinical use as a biomarker
Abstract To investigate aldo–keto reductase 1C3 (AKR1C3) expression in T and B acute lymphoblastic leukemia/lymphoma (ALL) patients. Three commercial antibodies were evaluated for AKR1C3 immunohistochemistry (IHC) staining performance: Polyclonal Thermofisher scientific (Clone#PA523667), rabbit mono...
Main Authors: | Deepti Reddi, Brandon W. Seaton, David Woolston, Lauri Aicher, Luke D. Monroe, Zhengwei J. Mao, Jill C. Harrell, Jerald P. Radich, Anjali Advani, Nikolaos Papadantonakis, Cecilia C. S. Yeung |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2022-04-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-022-09697-6 |
Similar Items
-
Mutational profiling in acute lymphoblastic leukemia by RNA sequencing and chromosomal genomic array testing
by: Cecilia Yeung, et al.
Published: (2021-08-01) -
Early precursor T-cell acute lymphoblastic leukemia: current paradigms and evolving concepts
by: Omar Castaneda Puglianini, et al.
Published: (2020-06-01) -
Enzymes of the AKR1B and AKR1C subfamilies and uterine diseases
by: Tea eLanisnik Rizner
Published: (2012-03-01) -
Solving the mystery of myelodysplasia.
by: Jerald Radich
Published: (2008-02-01) -
Structure-activity relationships of human AKR-type oxidoreductases involved in bile acid synthesis: AKR1D1 and AKR1C4.
by: Lee, W, et al.
Published: (2009)